SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis

FXR agonists have been investigated for the treatment of non-alcoholic steatohepatitis and liver fibrosis but the clinical efficacy is not optimal. Here the authors show that enhanced FXR SUMOylation in activated hepatic stellate cells reduces FXR signaling and that this can be rescued by SUMOylatio...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jiyu Zhou, Shuang Cui, Qingxian He, Yitong Guo, Xiaojie Pan, Pengfei Zhang, Ningning Huang, Chaoliang Ge, Guangji Wang, Frank J. Gonzalez, Hong Wang, Haiping Hao
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Q
Acceso en línea:https://doaj.org/article/cb0ac40b9ecd4e1ebc0d9be07e906d1a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!